3Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量：117
1Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广（译）,王淑敏（译）,胡大一（校）.极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志（中文版）,2006,25(4):215-223. 被引量：345
2Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量：117
4Libby P.Current concepts of the pathogenesis of the acute coronary syndromes[J].Circulation,2001; 104:365 -372. 被引量：1
5Nissen SE.High-dose statins in acute coronary syndromes:not just lipid leveb[J]..JAMA,2004i292:1307-1316. 被引量：1
6Jones PH,Davison MH,Stein EA,et al.Comparison of the efficacy and safety of rosuvastatin versus atorvastatin,simvastatin,and pravas-tatin across doses[J],Am J Cardiol,2003,92:152-160. 被引量：1
7Schuster H,Barter PJ,Slender S,et al.Effects of switching statins on achievement of lipid goal:Measuring effective reductions in cholesterol using rosuvastatin therapy study[J].Am Heart J,2004; 147:705 -712. 被引量：1
8Schwarts GG,Bolognese MA,Tremblay BP,et al.Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterol-emia and a high risk of coronary heart disease:a randomized,controlled trial[J].Am Heart J,2004;148:4. 被引量：1
9Anders GO.A new statin;a new standard[J].Clin Cardiol,2001; 24:18-23. 被引量：1
10Pearson TA,Mensah GA,Alexander RW,et al.Markers of inflammation and cardiovascular disease.Application to clinical and public health practice:a statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Asso-ciation[J].Cirulation,2003; 107:499 -511. 被引量：1
1Johnson N P, Gould K L. Clinical evaluation of a new concept, resting myocardial perfusion heterogeneity quantified bymarkovion analysis of PET identifies coronary microvascular dysfunction and early ath2 erosclerosis in 1 034 subjects [J]. J Nucl Med, 2012, 46(9): 1427-1437. 被引量：1
2Cohn J N, Duprez D A, Grandits G A. Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment [J]:Hypertension, 2010, 46(1): 217-220. 被引量：1
3Nissen S E, Nicholls S J, sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial [J]. JAMA, 2011, 295(13): 1556-1565. 被引量：1
